Captor Therapeutics SA
F:60Q
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Captor Therapeutics SA
F:60Q
|
PL |
|
C
|
China Overseas Land & Investment Ltd
F:CPP
|
HK |
|
Absa Group Ltd
F:AU6
|
ZA |
|
C
|
Captor Therapeutics SA
WSE:CTX
|
PL |
|
California Resources Corp
F:1CLD
|
US |
Intrinsic Value
Is 60Q undervalued or overvalued?
See the intrinsic value estimate for Captor Therapeutics SA and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Captor Therapeutics Does
Captor Therapeutics is a drug-discovery company that designs medicines based on targeted protein degradation. Instead of trying only to block a disease-causing protein, its approach aims to tag that protein for removal inside the cell. The company mainly works on early-stage research programs for hard-to-treat diseases, especially in oncology and other areas where new treatment options are needed.
- Headquarters
- Poland PL
- Employees
- 98
- IPO date
- Apr 19, 2021
Earnings Waterfall
Captor Therapeutics SA
The intrinsic value for Captor Therapeutics SA (60Q) under the Base Case is hidden EUR.
Compared with the current market price of 12.2 EUR, the stock appears hidden.